Key result
Surgical Impella 5.5 placement in 2 shock patients with prior TAVI shows no complications or regurgitation.
Why the study?
The use of Impella 5.5 in patients with transcatheter aortic valves (TAVI) remains rare and its safety and feasibility are not well established.
Is Impella 5.5 safe and feasible for managing refractory cardiogenic shock in patients with prior TAVI?
Population
2 male patients aged 74 years with refractory cardiogenic shock and prior TAVI
Comparison
Use of Impella 5.5 across Sapien 3 Ultra and Evolute Pro+ valves
Design
Case report
Authors
Loading...
Suggests Impella feasibility across TAVI in shock; hypothesis-generating and should not yet change practice.
Case Report (n=2)
Is Impella 5.5 safe and feasible for managing refractory cardiogenic shock in patients with prior TAVI?
Impella 5.5 implantation via axillary surgical cutdown is safe and feasible for managing refractory cardiogenic shock in patients with prior TAVI.
Harada et al. (2023) conducted a case report in Refractory cardiogenic shock with transcatheter aortic valves (n=2). Impella 5.5 was evaluated on Procedural complications or residual aortic or perivalvular regurgitation. Surgical placement of Impella 5.5 in two patients with cardiogenic shock and prior TAVI resulted in no procedural complications or residual aortic or perivalvular regurgitation.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: